Ipamorelin (5mg x 10), CJC-1295 no DAC (5mg x 10)

Ipamorelin and CJC-1295 no DAC (Mod GRF 1-29) are synthetic research peptides used together in experimental models to study growth hormone axis regulation and pituitary signaling dynamics. Ipamorelin is a selective pentapeptide growth hormone secretagogue that acts as an agonist of the growth hormone secretagogue receptor (GHS-R1a), activating Gq/PLC and calcium-dependent signaling pathways involved in GH release while exhibiting minimal interaction with other pituitary hormones in preclinical systems. CJC-1295 no DAC is a stabilized analog of growth hormone–releasing hormone (GHRH 1-29) that activates the GHRH receptor, stimulating adenylate cyclase and cAMP-mediated signaling in somatotroph cells. Preclinical research employs the combined activation of GHS-R1a and GHRH receptors to investigate synergistic somatotropic signaling, hypothalamic–pituitary feedback mechanisms, and peptide-mediated endocrine regulation.